Substance / Medication

Butenafine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Mycosis

Tinea pedis

Pityriasis versicolor

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w).

Mitra Amitava, Kim Nanhye, Spark Darren et al. · Regul Toxicol Pharmacol · 2016

PMID: 27816671Observational

Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin).

Tanuma H, Doi M, Ohta Y et al. · Mycoses · 2001

PMID: 11714064Observational

An in vitro release test method with Immersion Cells for evaluation of drug release performance of butenafine hydrochloride cream.

Li Ping, Zhang Rongqin, Li Xin et al. · Drug Dev Ind Pharm · 2026

PMID: 41400362Other

Formulation and Evaluation of Butenafine Hydrochloride-Incorporated Solid Lipid Nanoparticles as Novel Excipients for the Treatment of Superficial Fungal Infections.

Baviskar Anagha, Kashid Vivekanand, Ahirrao Sapana et al. · Turk J Pharm Sci · 2024

PMID: 39224083OtherFull text (PMC)

Accumulation of squalene in filamentous fungi Trichoderma virens PS1-7 in the presence of butenafine hydrochloride, squalene epoxidase inhibitor: biosynthesis of 13C-enriched squalene.

Zhang Wen, Sunami Kazu, Liu Shuo et al. · Biosci Biotechnol Biochem · 2023

PMID: 37528065Other

Determination of butenafine hydrochloride in human plasma by liquid chromatography electrospray ionization-mass spectrometry following its topical administration in human subjects.

Song Lin, Jiang Xuehua, Wang Ling · J Chromatogr B Analyt Technol Biomed Life Sci · 2011

PMID: 22005007Other

Stability-indicating LC assay for butenafine hydrochloride in creams using an experimental design for robustness evaluation and photodegradation kinetics study.

Barth Aline Bergesch, de Oliveira Gabriela Bolfe, Malesuik Marcelo Donadel et al. · J Chromatogr Sci · 2011

PMID: 21801482Other

Simultaneous HPLC determination of butenafine hydrochloride and betamethasone in a cream formulation.

Ankam R, Mukkanti K, Durgaprasad S et al. · Indian J Pharm Sci · 2009

PMID: 20502575OtherFull text (PMC)

Microemulsion-loaded hydrogel formulation of butenafine hydrochloride for improved topical delivery.

Pillai Anilkumar B, Nair Jyothilaksmi V, Gupta Nishant Kumar et al. · Arch Dermatol Res · 2015

PMID: 26006164Preclinical

A simple and rapid method to assess butenafine hydrochloride in skin samples and a comparative cutaneous retention study of two marketed formulations.

Barth Aline Bergesch, Pereira Rúbia Lazzaretti, de Vargas Bethânia Andrade et al. · Biomed Chromatogr · 2011

PMID: 21337350Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Butenafine hydrochloride (substance)
SNOMED CT: 108924009
UMLS CUI: C0771847

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.